Next-Gen CAR Platform Touts Potential of 1-Day Manufacturing
A single-day, cGMP-compliant manufacturing process to make a cryopreserved drug product, if successful, could dramatically reduce patient wait times.
Sarcoma News
SARCOMA CANCER ADVISOR
Sarcoma News
Hysterectomy Technique Tied to Poorer Uterine Cancer Outcomes
Uncontained uterine power morcellation tied to higher mortality in women with undetected uterine cancer.
Functional Outcomes Near Preoperative Levels After Surgery for Adult Soft Tissue Sarcoma
An analysis of how functional outcomes are measured in patients with soft tissue sarcoma revealed the efficacy of salvage surgery, and a need to improve frequency of FO measurements.
Clinical Trial Assesses Combination Chemotherapy With or Without Temsirolimus for Intermediate-Risk Rhabdomyosarcoma
Combination chemotherapy and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
The Accelerated Rise and Fall of Olaratumab in Sarcoma
Investigators from the ANNOUNCE trial suggested potential explanations for why there were such different outcomes across 2 of its trials.
Kaposi Sarcoma Treatment Gets Breakthrough Therapy Designation
The FDA has granted Breakthrough Therapy designation to Pomalyst (pomalidomide; Celgene) for the treatment of patients with Kaposi sarcoma.
Lartruvo Pulled From Market, Access Program to Be Established
Lilly is working to establish an access program to provide Lartruvo to patients who wish to continue treatment.
NRG1 Fusions Identified Across Solid Tumor Types
Detection across tumor types supports the use of next-generation sequencing.
Using Circulating MicroRNAs to Distinguish Benign Soft Tissue Tumors From Malignant Sarcomas
This study used comprehensive microarray analysis of serum to identify a panel of 7 miRNAs specific to sarcoma.
Adjuvant Chemotherapy Not Associated With Improved Survival in Stage I Uterine Leiomyosarcoma
According to researchers, older age and black race were independent predictors of poor OS in women with stage I uterine leiomyosarcoma.
FDA Recommends Against Initiating Olaratumab in Patients With Advanced Soft Tissue Sarcoma
FDA issued a statement recommending against the use of olaratumab in new patients with sarcoma following the release of negative results from the phase 3 ANNOUNCE trial.
Early Evidence that Larotrectinib Is Safe and Effective in Adults With Solid Tumors Characterized by TRK Fusions
Results from a phase 1 study suggest that larotrectinib could be a new standard of care in TRK-fusion cancers.
Imatinib Found to Be Effective in Unresectable Dermatofibrosarcoma Protuberans
Eight in 10 patients with DFSP saw a clinical benefit from treatment with imatinib.
Sorafenib for Advanced, Refractory Desmoid Tumors
Could sorafenib be the new standard of care for desmoid tumors?
mTOR Inhibition May Benefit Some Sarcoma Patients
mTOR inhibition is thought to enhance the efficacy of chemotherapy.
Induction ILP Prior to Surgery for ESTS Did Not Improve Patient Outcomes Compared With Standard of Care
The outcomes of patients with ESTS did not improve as a result of induction ILP prior to surgical intervention.
Olaratumab May Be Safe and Effective in Patients With Advanced Soft Tissue Sarcoma
The researchers conducted a retrospective cohort study of patients with advanced STS treated at a single institution over a 12 month period.
Next-Generation Sequencing May Benefit Some Patients With Sarcoma
Next generation sequencing (NGS) may be highly beneficial in select patients with sarcoma.
Most Utilized Frontline Treatment in Advanced Soft Tissue Sarcoma Across 4 European Countries
Approximately 70% of patients were administered anthracyclines as a primary therapy across patient datasets from France, Germany, Spain, and Italy.
Crizotinib as the Standard of Care in Advanced IMFT: Researchers Double Down on Proposal
Responses to crizotinib in ALK+ inflammatory myofibroblastic tumors were consistent with responses in ALK+ NSCLC, according to presenter Dr Schöffski.
Want to read more?
Please login or register first to view this content.
